HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers.
HER2 is over-expressed in around 15% to 20% of breast cancers. HER3 plays a critical role in HER2 mediated tumorigenesis. Increased HER3 transcription and protein levels occur upon inhibition of HER2. We aimed to identify proteins that bound to HER3 upon inhibition of the HER family with the pan-HER...
Main Authors: | Samar M Alanazi, Wasim Feroz, Rosalin Mishra, Mary Kate Kilroy, Hima Patel, Long Yuan, Sarah J Storr, Joan T Garrett |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0285251 |
Similar Items
-
HER3 Alterations in Cancer and Potential Clinical Implications
by: Mary Kate Kilroy, et al.
Published: (2022-12-01) -
HER3 signaling and targeted therapy in cancer
by: Rosalin Mishra, et al.
Published: (2018-05-01) -
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
by: Rosalin Mishra, et al.
Published: (2021-03-01) -
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
by: Hima Patel, et al.
Published: (2021-11-01) -
BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels
by: Long Yuan, et al.
Published: (2020-06-01)